TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34482102

Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg combined with camrelizumab 200 mg every 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anlotinib 8 mg combined with camrelizumab 200 mg every 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with brain metastasis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with ECOG 0 and 1
Number of subjects: 0
Study: 35704398

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LLBFR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-load nonBFR (LL)
Number of subjects: 14
Study: 34176622

Group type: EXPERIMENTAL
Intervention: Pair-housing (PH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individual housing (IH)
Number of subjects: 24
Study: 35803626

Group type: EXPERIMENTAL
Intervention: Monthly community-based testing for anaemia
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Participatory group education sessions
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Videos
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: Overall intervention (all components)
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3800
Study: 34729992

Group type: EXPERIMENTAL
Intervention: bioresorbable-polymer DES
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: durable-polymer DES
Number of subjects: 206

Group type: COMPARATOR
Intervention: high-dose acetylcholine (10−4 mol/L)
Number of subjects: 206

Group type: COMPARATOR
Intervention: bioactive DES
Number of subjects: 206

Group type: COMPARATOR
Intervention: low-dose acetylcholine
Number of subjects: 206

Group type: COMPARATOR
Intervention: high-dose acetylcholine
Number of subjects: 206
Study: 36271420

Group type: EXPERIMENTAL
Intervention: JX-594 combined with metronomic cyclophosphamide (arm 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metronomic cyclophosphamide (arm 2)
Number of subjects: 20
Study: 32743690

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Gadobutrol
Number of subjects: 134
Study: 33542928

Group type: EXPERIMENTAL
Intervention: Prodom-assisted urokinase treatment (PAUT)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Syringe-assisted urokinase treatment (SAUT)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Traditional treatment (TT)
Number of subjects: 261
Study: 34294478

Group type: EXPERIMENTAL
Intervention: Nonavalent vaccine HPV types
Number of subjects: 80
Study: 36065821

Group type: EXPERIMENTAL
Intervention: Early initiation of NOAC (≤4 days)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Delayed initiation of NOAC (5-10 days)
Number of subjects: 888
Study: 33914068

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence estimation using two immunoassays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with case-based surveillance data
Number of subjects: 0
Study: 34310714

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 25
Study: 33129360

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health economic analysis
Number of subjects: 0
Study: 34910390

Group type: EXPERIMENTAL
Intervention: Total mesometrial resection (TMMR) and therapeutic lymphadenectomy (tLNE)
Number of subjects: 116
Study: 32619694

Group type: EXPERIMENTAL
Intervention: Theta rTMS (6 Hz)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alpha rTMS (10 Hz)
Number of subjects: 20
Study: 33669552

Group type: EXPERIMENTAL
Intervention: Nature walk
Number of subjects: 13

Group type: COMPARATOR
Intervention: Urban walk
Number of subjects: 13
Study: 33678687

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 33123819

Group type: EXPERIMENTAL
Intervention: 100 mg of caffeine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35785574

Group type: EXPERIMENTAL
Intervention: tDCS (one trial of 20 min, 1 mA, cathodal electrodes placed bilaterally on the FPT areas)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham group (30 s tDCS treatment)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 22
Study: 34120651

Group type: EXPERIMENTAL
Intervention: remogliflozin etabonate 500 mg BID with metformin 2000 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: remogliflozin etabonate 750 mg BID with metformin 2000 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo BID with metformin 2000 mg
Number of subjects: 50
Study: 32443082

Group type: EXPERIMENTAL
Intervention: T. vaginalis positive cases (n = 45)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Control group (n = 45)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Pregnant girls with T. vaginalis (n = 26)
Number of subjects: 789
Study: 35646196

Group type: EXPERIMENTAL
Intervention: AR-assisted CPR
Number of subjects: 28

Group type: COMPARATOR
Intervention: Instructor-assisted CPR
Number of subjects: 28
Study: 32465759

Group type: EXPERIMENTAL
Intervention: Sternal-sparing approach
Number of subjects: 161

Group type: COMPARATOR
Intervention: Median sternotomy
Number of subjects: 161
Study: 33098117

Group type: EXPERIMENTAL
Intervention: Breast milk eye drops
Number of subjects: 312

Group type: COMPARATOR
Intervention: Sodium azulene sulphonate hydrate 0.02% ophthalmic solution
Number of subjects: 312
Study: 33397563

Group type: EXPERIMENTAL
Intervention: TWIN high
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: TWIN low
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: E‐BP
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: E‐ATRA
Number of subjects: 726

Group type: COMPARATOR
Intervention: VC
Number of subjects: 726
Study: 34953663

Group type: EXPERIMENTAL
Intervention: Swaddled bathing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional tub bathing
Number of subjects: 60
Study: 32279363

Group type: EXPERIMENTAL
Intervention: FIFA 11+ program executed twice a week for 20 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (regular warm-up)
Number of subjects: 71
Study: 35935332

Group type: EXPERIMENTAL
Intervention: Positive therapy and full perfusion therapy (combined with conventional therapy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 70
Study: 33251988

Group type: EXPERIMENTAL
Intervention: Running (RUN)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Elliptical training (ELIP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Resting recovery (REST)
Number of subjects: 64
Study: 35735106

Group type: EXPERIMENTAL
Intervention: NTS training program implemented during the second week of a 2-week rotation.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: NTS training program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (learners and teachers deciding together what should be learnt)
Number of subjects: 16
Study: 32757218

Group type: EXPERIMENTAL
Intervention: 3-month personalized treatment considering LPR characteristics at impedance-pH monitoring
Number of subjects: 127
Study: 36266483

Group type: EXPERIMENTAL
Intervention: Lidocaine injection method (LIM) during ESD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 50
Study: 33484307

Group type: EXPERIMENTAL
Intervention: PDS group (additional PDS cerclage with an 8-loop configuration over the AC joint)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-PDS group (bi-cortical CC-ligament reconstruction only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (PDS and No-PDS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PDS group
Number of subjects: 30
Study: 32227773

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Jiaji acupoints (EX-B2) plus moxibustion and intermediate frequency
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (traditional acupuncture)
Number of subjects: 140
Study: 35289266

Group type: EXPERIMENTAL
Intervention: Virtual reality-based exercise (VRBE) intervention, 45 minutes per session, 2 days a week for 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group managed with supportive measures
Number of subjects: 38
Study: 33468598

Group type: EXPERIMENTAL
Intervention: Video interpretation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Telephone interpretation
Number of subjects: 50
Study: 35725851

Group type: EXPERIMENTAL
Intervention: Hernial sac ligation (HL)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-ligation/invagination (non-HL)
Number of subjects: 93
Study: 34636521

Group type: EXPERIMENTAL
Intervention: Bioelectric Muscle Activation (BMA) system (Accufit)TM; treatment regimen: four 30-minute sessions
Number of subjects: 29
Study: 32101630

Group type: EXPERIMENTAL
Intervention: Lifestyle development program conducted over 7 months with group activities once a month and daily individual activities.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0
Study: 35085524

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 768

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 768
Study: 33181142

Group type: EXPERIMENTAL
Intervention: 2% IDL lotion applied over 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethyl linoleate/oleate
Number of subjects: 0
Study: 36078584

Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRV-G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT-G)
Number of subjects: 0
Study: 32443357

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation + norepinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation + norepinephrine + ulinastatin (20,000 U/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 60
Study: 33461385

Group type: EXPERIMENTAL
Intervention: Chitin-glucan (CG) 4.5 g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maltodextrin (placebo) 4.5 g
Number of subjects: 15
Study: 33245242

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose corticosteroid therapies
Number of subjects: 0
Study: 33710427

Group type: EXPERIMENTAL
Intervention: Transvaginal uterosacral ligament suspension (USLS)
Number of subjects: 186
Study: 32711471

Group type: EXPERIMENTAL
Intervention: Searching CENTRAL
Number of subjects: 247
Study: 34952812

Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation for 8 weeks, weekly 20-minute sessions with voluntary contraction attempts during the last 10 minutes of each session.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group received no intervention.
Number of subjects: 64
Study: 34826341

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure goal of <120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Adjudicated MCI
Number of subjects: 9361
Study: 32334166

Group type: EXPERIMENTAL
Intervention: Temporary and reactive responses to climate-related hazards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strengthening adaptive infrastructure (physical and informational)
Number of subjects: 0
Study: 35997037

Group type: EXPERIMENTAL
Intervention: Traction ESD (T-ESD)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Conventional ESD (C-ESD)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Traction ESD (T-ESD) for lesions ≥30 mm
Number of subjects: 251

Group type: COMPARATOR
Intervention: Conventional ESD (C-ESD) for lesions ≥30 mm
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Traction ESD (T-ESD) by nonexpert operators
Number of subjects: 251

Group type: COMPARATOR
Intervention: Conventional ESD (C-ESD) by nonexpert operators
Number of subjects: 251
Study: 34185627

Group type: EXPERIMENTAL
Intervention: Scenarios set in the present
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Scenarios set in the past
Number of subjects: 188
Study: 35235550

Group type: EXPERIMENTAL
Intervention: HPV vaccine (Gardasil or Gardasil 9)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Active control (AC) - Avaxim, a hepatitis A vaccine
Number of subjects: 273
Study: 32556348

Group type: EXPERIMENTAL
Intervention: Rolling cane (Wheeleo®)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Classical quadripod cane
Number of subjects: 32
Study: 36115814

Group type: EXPERIMENTAL
Intervention: INOCA patients (n=476)
Number of subjects: 3612

Group type: COMPARATOR
Intervention: Moderate or severe ischemia
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3612
Study: 32960320

Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT)
Number of subjects: 10
Study: 32380954

Group type: EXPERIMENTAL
Intervention: Soft Seal® (Portex®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AuraOnce™ (Ambu®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LMA‐Classic™ (Teleflex®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LMA‐ProSeal™ (Teleflex®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Maximum recommended volume
Number of subjects: 80
Study: 35816815

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal protein diet (NP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nutritional meal replacement (MR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (HP, NP, MR)
Number of subjects: 60
Study: 34183800

Group type: EXPERIMENTAL
Intervention: Brief interventions that increase subjective understanding of algorithmic decision processes
Number of subjects: 2699

Group type: EXPERIMENTAL
Intervention: Algorithmic skin cancer detection app
Number of subjects: 2699
Study: 32833136

Group type: EXPERIMENTAL
Intervention: Eribulin in combination with trastuzumab and pertuzumab
Number of subjects: 50
Study: 32781441

Group type: EXPERIMENTAL
Intervention: 70% 1-RM bench press
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 70% 1-RM squat (squat-70%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 80% 1-RM squat (squat-80%)
Number of subjects: 20
Study: 35276991

Group type: EXPERIMENTAL
Intervention: Probiotics (group A)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 664
Study: 35125253

Group type: EXPERIMENTAL
Intervention: Communities that HEAL (CTH) intervention implementing evidence-based practices (EBPs) to reduce opioid overdose deaths
Number of subjects: 382

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 382
Study: 34195102

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot supplement
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water intake
Number of subjects: 12
Study: 35110416

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus anthracycline or non-anthracycline chemotherapy
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy
Number of subjects: 662

Group type: COMPARATOR
Intervention: Control group (non-trastuzumab treated patients)
Number of subjects: 662
Study: 33794441

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 0
Study: 36219614

Group type: EXPERIMENTAL
Intervention: Plasma microRNA-221-3p levels at 1 day before and 7 days after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma microRNA-221-3p levels at 7 days after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma microRNA-221-3p at postoperative 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: POCD diagnosis
Number of subjects: 0
Study: 33773275

Group type: EXPERIMENTAL
Intervention: SN resection alone (SN arm)
Number of subjects: 206

Group type: COMPARATOR
Intervention: SN + PLND arm
Number of subjects: 206
Study: 33524646

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional saline dressings
Number of subjects: 45
Study: 33817779

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD)
Number of subjects: 10788
Study: 35870332

Group type: EXPERIMENTAL
Intervention: Olive oil massage
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 42
Study: 34518245

Group type: EXPERIMENTAL
Intervention: web‐based connected device (activity tracker, smartphone application, website)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: therapeutic patient education (one educational diagnosis, two collective educational sessions, one evaluation)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: combination of both interventions
Number of subjects: 432

Group type: COMPARATOR
Intervention: control (usual care)
Number of subjects: 432
Study: 37078430

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 30
Study: 34898896

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vaginal progesterone 600 mg/day
Number of subjects: 200
Study: 33929938

Group type: EXPERIMENTAL
Intervention: Access to 10 adaptive learning modules during the dermatology rotation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No access to adaptive learning modules during the dermatology rotation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 0
Study: 32427813

Group type: EXPERIMENTAL
Intervention: Standardized education session on the Walter Reed HO classification system followed by 2 grading sessions
Number of subjects: 100
Study: 36841463

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg IUD
Number of subjects: 318

Group type: COMPARATOR
Intervention: Copper 380 mm2 IUD
Number of subjects: 318

Group type: COMPARATOR
Intervention: Levonorgestrel 19.5 mg IUD
Number of subjects: 318
Study: 33443874

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 83
Study: 32745964

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 3265
Study: 36123938

Group type: EXPERIMENTAL
Intervention: High-quality nursing (n = 192)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Normal nursing (n = 180)
Number of subjects: 372
Study: 33856324

Group type: COMPARATOR
Intervention: No difficult airway characteristics
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: One or more anatomically difficult airway characteristics
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: One or more physiologically difficult airway characteristics
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Both anatomically and physiologically difficult airway characteristics
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Anatomically difficult airway characteristics
Number of subjects: 1513

Group type: EXPERIMENTAL
Intervention: Physiologically difficult airway characteristics
Number of subjects: 1513
Study: 35213459

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage using 10 L normal saline
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage using distilled water
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group with no lavage
Number of subjects: 193
Study: 35980169

Group type: EXPERIMENTAL
Intervention: Treatment for asymptomatic bacteriuria (AB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment for asymptomatic bacteriuria (AB)
Number of subjects: 80
Study: 33940954

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3941

Group type: COMPARATOR
Intervention: Aspirin alone (Control)
Number of subjects: 3941

Group type: EXPERIMENTAL
Intervention: Presence of ≥50% carotid stenosis
Number of subjects: 3941
Study: 33110037

Group type: EXPERIMENTAL
Intervention: Increased levels of cognitive complaints
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms and somatic complaints
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Memory tasks performance
Number of subjects: 44
Study: 36401652

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops, administered once nightly for 1 year
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops, administered for 6 months after crossover
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops
Number of subjects: 105
Study: 33658764

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neostigmine 40 µg/kg
Number of subjects: 80
Study: 36051482

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the theory of planned behavior (TPB) consisting of five sessions of 45‐60 minutes
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study: 33744202

Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions written by general practitioners (GPs)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions written by nurses
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions for skin and soft-tissue infection
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antimicrobial prescriptions for lower respiratory-tract infection
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, amoxicillin-clavulanate, and cefalexin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall antimicrobial prescribing in remote clinics
Number of subjects: 180
Study: 35251398

Group type: COMPARATOR
Intervention: Paravertebral nerve block (PVB)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Superficial serratus anterior plane block (SSPB)
Number of subjects: 74
Study: 33087111

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg daily orally at 21:00 for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo daily orally at 21:00 for 28 days
Number of subjects: 60